Commercializationv1 · 09.29
Signatera: Using Tumor DNA in Blood to Guide Treatment After Surgery ↗
How can molecular evidence of residual cancer guide postoperative treatment?
Natera announced Japanese companion-diagnostic approval; additional treatment in test-positive patients has been assessed in a comparative trial.
- Reports and agreements reviewedRecorded
- Further validationUnverified
- Adoption and benefitUnverified
New question opened
Recorded a new question and follow-up checks from the approved manuscript.
NEXT CHECK
Track the authorized population and treatment conditions.
Evidence: www.natera.com ↗www.accessdata.fda.gov ↗